CB-5083 potently inhibits myeloma viability in vitro

Rapid cell kill of myeloma cells exposed to CB-5083 by Timelapse-CS-BLI

CB-5083 inhibits growth in an orthotopic metastatic model of myeloma

CB-5083 reduces M-spike in Vk*MYC mouse model of myeloma

CB-5083 treatment synergizes with a lenalidomide-dexamethasone regimen

Sensitivity of myeloma to CB-5083 differentiates from proteasome inhibitors

Figure 8. Pharmacokinetics of CB-5083 in a mouse orthotopic xenograft model of MM with KMS11 luciferase MM cells. 

Figure 10. Tumor growth curves and circulating light chains in myeloma xenograft models treated with a single agent or combination therapy. 

Figure 11: Correlation of potencies between CB-5083 and proteasome inhibitors 

Figure 12: Evaluation of CB-5083 potency and the presence of luciferase expression in MM cells from a single agent versus combination treatment arms. 

Figure 13: CB-5083 reduces lambda light chain levels in Vk*MYC mice. (A) Absolute protein levels in serum were measured in KMS11 cells following 14-day CB-5083 treatment. (B) Relative gene expression measured by qPCR for the indicated genes. 

CB-5083 potently inhibits myeloma viability in vitro

Rapid cell kill of myeloma cells exposed to CB-5083 by Timelapse-CS-BLI

CB-5083 inhibits growth in an orthotopic metastatic model of myeloma

CB-5083 reduces M-spike in Vk*MYC mouse model of myeloma

CB-5083 treatment synergizes with a lenalidomide-dexamethasone regimen

Sensitivity of myeloma to CB-5083 differentiates from proteasome inhibitors

Figure 8. Pharmacokinetics of CB-5083 in a mouse orthotopic xenograft model of MM with KMS11 luciferase MM cells. 

Figure 10. Tumor growth curves and circulating light chains in myeloma xenograft models treated with a single agent or combination therapy. 

Figure 11: Correlation of potencies between CB-5083 and proteasome inhibitors 

Figure 12: Evaluation of CB-5083 potency and the presence of luciferase expression in MM cells from a single agent versus combination treatment arms. 

Figure 13: CB-5083 reduces lambda light chain levels in Vk*MYC mice. (A) Absolute protein levels in serum were measured in KMS11 cells following 14-day CB-5083 treatment. (B) Relative gene expression measured by qPCR for the indicated genes.